Global Women's Health Therapeutics Market 2022


Description

The global women’s health therapeutics market is poised to grow by US$ 21.1 billion during 2022-2028, progressing at a CAGR of 5.4% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for women’s health therapeutics. The global women’s health therapeutics market is segmented on the basis of indication, and region. By indication, the global women’s health therapeutics market has been segmented into breast cancer, endometriosis, menopause, polycystic ovary syndrome (PCOS), postmenopausal osteoporosis. The breast cancer segment was the largest contributor to the global women’s health therapeutics market in 2021. Geographically, the global women’s health therapeutics market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). According to the research, North America had the largest share in the global women’s health therapeutics market.

The global women’s health therapeutics market is highly competitive. Key companies profiled in the report include AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., The Bristol-Myers Squibb Company (BMS). Competitive landscape gives a description of the competitive nature of the global women’s health therapeutics market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the women’s health therapeutics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.


Report Scope

Indication: breast cancer, endometriosis, menopause, polycystic ovary syndrome (PCOS), postmenopausal osteoporosis
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., The Bristol-Myers Squibb Company (BMS)


Key Benefits for Stakeholders

– Get a comprehensive picture of the global women’s health therapeutics market
– Pinpoint growth sectors and trends for investment


Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Women’s health therapeutics market overview
Part 3. Market breakdown by indication
– Breast cancer
– Endometriosis
– Menopause
– Polycystic ovary syndrome (PCOS)
– Postmenopausal osteoporosis
Part 4. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 5. Key companies
– AbbVie Inc.
– Amgen Inc.
– AstraZeneca plc
– Bayer AG
– Daiichi Sankyo Company, Limited
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– Gilead Sciences, Inc.
– Johnson & Johnson
– Merck KGaA
– Novartis AG
– Novo Nordisk A/S
– Pfizer Inc.
– Sanofi S.A.
– The Bristol-Myers Squibb Company (BMS)
About StrategyHelix
Disclaimer


USD 450

Want to customize this report? Our industry specialist will collaborate with you to deliver tailored data within a limited timeframe.
Scroll to Top

Request Free Sample Report

Global Women's Health Therapeutics Market 2022

Please fill out our form and we will get back to you.

CUSTOM RESEARCH

Global Women's Health Therapeutics Market 2022

Please fill out our form and we will get back to you.

login